Listen to this article
Use the audio reader to listen while you read.
Screening, Treatment, and Controversy at the Intersection of Science, Policy, and Men’s Health
Prostate cancer is the most frequently diagnosed solid malignancy in men in many countries and a leading cause of cancer death worldwide. Global estimates suggest more than 1.4 million new cases and substantial mortality each year, with large regional and racial differences in incidence and outcomes. This article reviews epidemiology, risk factors, clinical features, diagnosis, and management of prostate cancer, then examines scholarly and critical debates surrounding prostate-specific antigen (PSA)–based screening, overdiagnosis, overtreatment, and health inequities.
Evidence from randomized trials and modeling studies supports a mortality benefit from screening but also demonstrates high rates of overdiagnosis and treatment-related morbidity. Major guideline groups now emphasize shared decision-making and risk-adapted strategies, while some researchers and critics argue that policies either under-protect high-risk groups or still expose too many men to unnecessary interventions. The article concludes with implications for practice and policy and suggests key readings for further study.
Keywords: prostate cancer, PSA screening, overdiagnosis, active surveillance, health disparities, shared decision-making
1. Prostate Cancer
Prostate cancer is a malignant tumor arising from the glandular epithelium of the prostate and is currently the second most commonly diagnosed cancer in men globally and the fifth leading cause of cancer death.PMC+2Frontiers+2 According to the GLOBOCAN 2020 estimates, more than 1.4 million new cases were diagnosed worldwide, with substantial geographic variation in incidence and mortality.Frontiers+2PubMed+2
Over recent decades, widespread use of PSA testing has dramatically altered the epidemiology of prostate cancer, increasing detection of early-stage disease but also raising concerns about overdiagnosis and overtreatment.CNIB+2Gouvernement de la Colombie-Britannique+2 These trends have generated intense debate among clinicians, epidemiologists, health-policy scholars, and patient advocates.
For general readers, accessible overviews are available from the U.S. National Cancer Institute (https://www.cancer.gov/types/prostate) and the American Cancer Society (https://www.cancer.org/cancer/prostate-cancer.html).
2. Epidemiology and Global Burden
Population-level data from GLOBOCAN and the Global Cancer Observatory (https://gco.iarc.fr/) show that age-standardized incidence rates are highest in North America, Western and Northern Europe, and Oceania, and lower in most parts of Asia and Africa.Frontiers+2Observatoire Mondial du Cancer+2 Differences are influenced by PSA testing practices, life expectancy, genetic background, diet, and health-system capacity.
Rawla (2019) notes that prostate cancer may be asymptomatic for long periods and that many men die with, rather than from, the disease.PMC Conversely, in low-resource settings where screening is limited and access to treatment is constrained, men often present with advanced disease and poorer survival.Frontiers+1
Recent global trend analyses indicate that incidence and mortality are rising in several countries in Africa, Asia, and Latin America, reflecting demographic aging and lifestyle changes, but also uneven access to early detection and high-quality treatment.ScienceDirect+2Frontiers+2
3. Risk Factors and Pathophysiology
Established risk factors include:
- Age: Risk increases sharply after age 50.PMC+1
- Race / ancestry: Men of African descent, particularly African American and Afro-Caribbean men, have higher incidence and mortality.PMC+2OUP Academic+2
- Family history and genetics: First-degree relatives with prostate cancer approximately double risk; genome-wide association studies have identified numerous susceptibility loci.OUP Academic+1
- Lifestyle and environmental factors: Diet, obesity, physical inactivity, and possibly some occupational exposures have been implicated, though evidence is mixed.PMC+1
Prostate carcinogenesis is driven by a complex interplay of androgen signaling, genomic instability, and microenvironmental factors. Detailed mechanistic descriptions are available in the StatPearls chapter on prostate cancer (https://www.ncbi.nlm.nih.gov/books/NBK470550/). CNIB
4. Clinical Presentation, Diagnosis, and Risk Stratification
4.1 Presentation
Many prostate cancers are detected while asymptomatic via PSA testing. Symptomatic men may present with lower-urinary-tract symptoms, hematuria, or, in advanced disease, bone pain and weight loss.CNIB+1
4.2 Diagnostic Work-up
Standard diagnostic steps include:
- PSA measurement and digital rectal examination (DRE)
- Imaging (e.g., MRI) to guide biopsy and staging
- Transrectal or transperineal ultrasound-guided biopsy for histologic confirmation
Contemporary practice increasingly uses multiparametric MRI and risk calculators to improve specificity and reduce unnecessary biopsies.emedicine.medscape.com+1
4.3 Risk Stratification
After diagnosis, risk is typically stratified using PSA level, clinical T-stage, and Gleason Grade Group, often combined into schemes such as NCCN risk categories (very low, low, intermediate, high, very high).PubMed+2jnccn.org+2 These stratifications guide treatment choices, from active surveillance for very-low-risk disease to multimodal therapy for high-risk or metastatic cancer. Patient-friendly explanations are available in the NCCN Guidelines for Patients (https://www.nccn.org/patients/guidelines/prostate). nccn.org+1
5. Management: From Active Surveillance to Advanced Disease
Treatment depends on stage, risk category, comorbidities, and patient preference.PubMed+2CNIB+2
- Active surveillance: Regular monitoring with PSA, DRE, and repeat biopsies/MRI for very-low and some low-risk cancers; aims to avoid or delay curative treatment and its side effects.PubMed+1
- Definitive local therapy: Radical prostatectomy (often robotic) or radiation therapy (external beam, brachytherapy) for localized disease.CNIB+1
- Androgen-deprivation therapy (ADT): Surgical or medical castration (e.g., LHRH agonists/antagonists) for advanced or recurrent disease.CNIB+1
- Novel systemic treatments: Next-generation androgen-receptor inhibitors, PARP inhibitors for selected patients with DNA-repair defects, and radioligand therapies in metastatic castration-resistant prostate cancer.PubMed+1
While these treatments can be life-prolonging, they also carry risks of urinary incontinence, erectile dysfunction, bowel symptoms, metabolic changes, and quality-of-life impacts, which figure heavily in current debates about screening and treatment thresholds.Gouvernement de la Colombie-Britannique+1
6. Screening and Early Detection: Evidence and Controversies
6.1 PSA Screening: Mortality Benefits and Harms
Randomized trials such as the European Randomized Study of Screening for Prostate Cancer (ERSPC) have shown that PSA-based screening can reduce prostate-cancer mortality by roughly 20% at the population level, at the cost of substantial overdiagnosis.ScienceDirect+1 Overdiagnosis refers to detection of cancers that would not have caused symptoms or death during a man’s lifetime, exposing patients to biopsy risks and possible overtreatment.Gouvernement de la Colombie-Britannique+1
A harm-benefit analysis in NEJM Evidence estimated that, over three decades of PSA screening in the United States, deaths were averted but many men experienced overdiagnosis and treatment-related side effects.evidence.nejm.org Modeling studies suggest that the trade-off may be more favorable for some high-risk groups (e.g., Black men, men with strong family history).OUP Academic+1
6.2 Guideline Positions and Shared Decision-Making
Reflecting this mixed evidence, major guideline bodies have adopted nuanced positions:
- The U.S. Preventive Services Task Force (USPSTF) recommends that men aged 55–69 engage in shared decision-making about PSA-based screening and advises against routine screening for men ≥70.uspreventiveservicestaskforce.org+2uspreventiveservicestaskforce.org+2 Full details are available at https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening.
- The U.S. Centers for Disease Control and Prevention (CDC) provides patient-oriented guidance emphasizing individualized decisions for men 55–69 and discouraging routine screening after 70 (https://www.cdc.gov/prostate-cancer/screening/get-screened.html). CDC
- The American Academy of Family Physicians and other primary-care groups broadly align with this approach, stressing shared decision-making.AAFP
Clinical critics who are skeptical of widespread PSA screening argue that evidence of mortality benefit is modest and that harms from overdiagnosis and overtreatment are substantial, particularly when screening is applied indiscriminately.ScienceDirect+1 Some public-health scholars point out that resources invested in mass screening might yield greater benefit if directed to modifiable risk factors and treatment access.
By contrast, other experts—especially those focused on high-risk populations—argue that current guidelines may be too conservative for Black men or those with strong family histories, potentially missing aggressive cancers at curable stages.The Washington Post+3PMC+3OUP Academic+3
7. Health Equity and Racial / Ethnic Disparities
Prostate cancer exemplifies how biological risk intersects with structural inequity. In the United States and Canada, men of African descent have higher incidence, present with more advanced disease, and experience higher mortality than White men.PMC+2PMC+2
Studies report that Black men are more likely to be diagnosed with higher-grade tumors and less likely to receive guideline-concordant care, including timely biopsies, MRI, and definitive treatment.PMC+2JAMA Network+2 At the same time, they face higher risks of overdiagnosis and treatment side effects if screened and treated aggressively.OUP Academic+1
Researchers like Kensler et al. (2023) and Otiono et al. (2022) call for race-conscious yet equity-focused screening strategies—such as earlier or more frequent PSA testing for high-risk men, combined with efforts to ensure informed consent, robust active-surveillance pathways, and equal access to advanced diagnostics.PMC+1 Critics caution that using race alone as a proxy for risk can inadvertently reinforce biological essentialism; they advocate focusing on ancestry, family history, and social determinants of health instead.OUP Academic+1
8. Selected Tables
Table 1
Global Prostate Cancer Burden (GLOBOCAN 2020 Estimates)
| Indicator (2020) | Value | Notes / Source |
|---|---|---|
| New prostate cancer cases worldwide | >1.4 million | Approximate global count of incident cases.Frontiers+1 |
| Global crude incidence rate | 36.0 per 100,000 males | Substantial variation by region.Frontiers |
| Age-standardized incidence rate (ASIR) | 30.7 per 100,000 males | Highest in Europe, North America, Oceania.Frontiers+1 |
| Global deaths from prostate cancer | ~375,000 | Part of ~10 million total cancer deaths in 2020.PubMed+1 |
| Ranking among male cancers | #1 in incidence in many high-income countries | Commonest male cancer in several Western nations.ScienceDirect+1 |
Table 2
PSA Screening Recommendations and Key Points (Selected Organizations)
| Organization | Age Range | Recommendation | Key Emphasis |
|---|---|---|---|
| USPSTF (U.S.) | 55–69 | Individual decision after counseling (Grade C) | Discuss benefits/harms; no routine screening ≥70 (Grade D).uspreventiveservicestaskforce.org+1 |
| CDC (U.S.) | 55–69 | Encourage shared decision-making; no routine screening ≥70 | Patient-friendly explanations and decision aids.CDC |
| AAFP | 55–69 | Shared decision-making; align with USPSTF | Primary-care focus; caution about overdiagnosis.AAFP |
| NCCN (U.S., specialty) | Typically from 45–75, with risk-based nuance | Risk-adapted PSA testing for average vs high-risk men; repeat intervals vary by baseline PSA | More favorable toward targeted early detection; integrates MRI and risk stratification.PubMed+2jnccn.org+2 |
| Critics (various scholars) | — | Some advocate more aggressive screening in high-risk groups (e.g., Black men, strong family history); others argue for further de-implementation | Ongoing debate over balancing mortality reduction vs overdiagnosis, especially across racial and socio-economic lines.Gouvernement de la Colombie-Britannique+3OUP Academic+3PMC+3 |
9. Conclusions
Prostate cancer sits at the crossroads of aging, biology, technology, and policy. Evidence shows that PSA-based screening and modern treatments can reduce mortality, yet the benefits are unevenly distributed and accompanied by significant harms. The resulting debates among scholars, clinicians, and critics are less about whether prostate cancer matters—it clearly does—and more about how society should prioritize early detection, whom to target, and how to ensure that men are genuinely informed participants in decisions that may shape their quality of life for decades.
Future directions include refining risk-prediction tools; expanding MRI-based pathways and active surveillance; addressing racial and socio-economic disparities in access and outcomes; and strengthening shared decision-making in primary care. Prostate cancer policy will remain contested, but that contestation, when grounded in evidence and equity, can be a productive force for improving men’s health worldwide.
10. Suggested Further Readings:
- Rawla, P. (2019). Epidemiology of prostate cancer. World Journal of Oncology. Overview of global patterns and risk factors.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6497009/ PMC - Wang, L., et al. (2022). Prostate cancer incidence and mortality: Global status and trends. Frontiers in Public Health. Detailed analysis of GLOBOCAN 2020 data.
https://www.frontiersin.org/articles/10.3389/fpubh.2022.811044/full Frontiers - Schaeffer, E. M., et al. (2024). NCCN Guidelines Insights: Prostate cancer. JNCCN. Key updates on risk stratification and management.
https://jnccn.org/view/journals/jnccn/22/3/article-p140.xml PubMed+1 - US Preventive Services Task Force (2018). Prostate cancer screening recommendation. Official guideline and evidence review.
https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening uspreventiveservicestaskforce.org+1 - Obiora, D., et al. (2025). Controversies in prostate cancer screening. Urologic Oncology. Contemporary review of PSA screening debates.
(Abstract and access via ScienceDirect) https://www.sciencedirect.com/science/article/abs/pii/S1078143924005349 ScienceDirect - Nyame, Y. A., et al. (2021). Impact of intensifying prostate cancer screening in Black men. JNCI. Modeling harm–benefit trade-offs in high-risk populations.
https://academic.oup.com/jnci/article/113/10/1336/6272520 OUP Academic - Kensler, K. H., et al. (2023). Prostate cancer screening in African American men. Current Opinion in Urology. Discussion of risk, inequities, and policy.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10777677/ PMC - BC Guidelines (2020). Prostate cancer Part 1: Diagnosis and referral in primary care. Clear explanation of PSA controversy for clinicians.
https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines/prostate-cancer-part-1 Gouvernement de la Colombie-Britannique - NCI – “Prostate Cancer Treatment (PDQ®)” Extensive, regularly updated treatment guideline for clinicians and patients.
https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq
11. References:
(Format according to APA 7th edition; not an exhaustive list.)
Rawla, P. (2019). Epidemiology of prostate cancer. World Journal of Oncology, 10(2), 63–89. PMC
Schaeffer, E. M., et al. (2024). NCCN Guidelines Insights: Prostate cancer, version 1.2024. Journal of the National Comprehensive Cancer Network, 22(3), 140–152. PubMed+1
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates. CA: A Cancer Journal for Clinicians, 71(3), 209–249. PubMed+1
U.S. Preventive Services Task Force. (2018). Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA, 319(18), 1901–1913. uspreventiveservicestaskforce.org+2uspreventiveservicestaskforce.org+2
Wang, L., et al. (2022). Prostate cancer incidence and mortality: Global status and trends. Frontiers in Public Health, 10, 811044. Frontiers
Nyame, Y. A., Gulati, R., Tsodikov, A., et al. (2021). Impact of intensifying prostate cancer screening in Black men. Journal of the National Cancer Institute, 113(10), 1336–1345. OUP Academic
Kensler, K. H., et al. (2023). Prostate cancer screening in African American men. Current Opinion in Urology, 33(3), 213–220. PMC
Obiora, D., et al. (2025). Controversies in prostate cancer screening. Urologic Oncology: Seminars and Original Investigations, 43(x), xxx–xxx. ScienceDirect